{"transactions":[{"id":724106,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:38:30.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":5.5,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-26-000305","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071726000305/form4.xml","form_type":"4"}},{"id":1101098,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-26T20:30:19.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":7.63,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-25-000256","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000256/form4.xml","form_type":"4"}},{"id":1436936,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-09T20:08:56.000Z","date":"2024-08-07","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the total number of shares vest in thirty-six (36) successive and equal monthly installments measured from August 7, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":120000,"derivative":{"exercise_price":0.55,"expiration_date":"2034-08-07","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001610717-24-000422","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000422/form4.xml","form_type":"4"}},{"id":1856006,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T17:10:42.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":4.64,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-23-037096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919123037096/doc4.xml","form_type":"4"}},{"id":2098378,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-12-02T16:49:31.000Z","date":"2022-12-01","kind":"disposition_to_issuer","acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the merger (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option to purchase Shares having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option and (y) one CVR for each Share subject to such option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the merger (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option to purchase Shares having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option and (y) one CVR for each Share subject to such option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":4.21,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-22-124137","document":"tm2231851-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465922124137/tm2231851-4_4seq1.xml","form_type":"4"}},{"id":2098377,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-02T16:49:31.000Z","date":"2022-11-30","kind":"other","acquired":false,"shares":5882,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest (the \"Cash Consideration\") and less any applicable tax withholding, plus [Continued on Note 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[Continuation of Note 1] (ii) one non-tradable contingent value right (\"CVR\") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest (the \"Cash Consideration\") and less any applicable tax withholding, plus [Continued on Note 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[Continuation of Note 1] (ii) one non-tradable contingent value right (\"CVR\") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-22-124137","document":"tm2231851-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465922124137/tm2231851-4_4seq1.xml","form_type":"4"}},{"id":2221181,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-27T17:06:05.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 23, 2022. The shares underlying the option will fully vest on the earlier of (i) June 23, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The option was granted to the Reporting Person, a managing partner of Pivotal BioVenture Partners Fund I, L.P. (the \"Fund\") and an officer of Pivotal bioVenture Partners Investment Advisor, LLC (the \"Investment Adviser\"), the Fund's investment adviser, in connection with her service as a member of the Board of Directors of the Issuer. Pursuant to the policies of the Investment Adviser, the Reporting Person has assigned her rights in respect of the option to the Investment Adviser. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein, if any."}],"balance_after":16000,"derivative":{"exercise_price":4.21,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-22-074834","document":"tm2219359-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465922074834/tm2219359-6_4seq1.xml","form_type":"4"}},{"id":2224242,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T19:16:36.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 14, 2023 or (ii) the 2023 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":3.6,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-22-038773","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919122038773/doc4.xml","form_type":"4"}},{"id":2653076,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-28T21:31:37.000Z","date":"2021-06-24","kind":"other","acquired":true,"shares":184,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a distribution of common stock of the Issuer to partners of a limited partnership and includes subsequent distributions by the general partner of the limited partnership."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a distribution of common stock of the Issuer to partners of a limited partnership and includes subsequent distributions by the general partner of the limited partnership."}],"balance_after":6556,"source":{"system":"sec-edgar","filing":"0001062993-21-006041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000106299321006041/form4.xml","form_type":"4"}},{"id":2654831,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-25T16:37:45.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 24, 2021. The shares underlying the option will fully vest on the earlier of (i) June 24, 2022 and (ii) the date of the Issuer's 2022 annual meeting of stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The option was granted to the Reporting Person, a managing partner of Pivotal BioVenture Partners Fund I, L.P. (the \"Fund\") and an officer of Pivotal bioVenture Partners Investment Advisor, LLC (the \"Investment Adviser\"), the Fund's investment adviser, in connection with her service as a member of the Board of Directors of the Issuer. Pursuant to the policies of the Investment Adviser, the Reporting Person has assigned her rights in respect of the option to the Investment Adviser. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein, if any."}],"balance_after":16000,"derivative":{"exercise_price":13.39,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-21-085764","document":"tm2120686-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465921085764/tm2120686-5_4seq1.xml","form_type":"4"}},{"id":2656765,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-06-23T20:39:09.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 16, 2022, and (ii) the 2022 annual meeting of the Issuer's stockholders."}],"balance_after":8500,"derivative":{"exercise_price":128.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001593968-21-001688","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000159396821001688/primary_01.xml","form_type":"4"}},{"id":2679494,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-07T16:18:05.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 4, 2022 or (ii) the 2022 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":8.15,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-21-038583","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919121038583/doc4.xml","form_type":"4"}},{"id":2796224,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T00:25:22.000Z","date":"2021-03-08","kind":"other","acquired":true,"shares":572,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a distribution of common stock of the Issuer to partners of a limited partnership and includes subsequent distributions by the general partner of the limited partnership."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a distribution of common stock of the Issuer to partners of a limited partnership and includes subsequent distributions by the general partner of the limited partnership."}],"balance_after":6372,"source":{"system":"sec-edgar","filing":"0001062993-21-002589","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000106299321002589/form4.xml","form_type":"4"}},{"id":3035093,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-10T00:10:43.000Z","date":"2020-09-04","kind":"purchase","acquired":true,"shares":350,"price":72.36,"value":25326.0,"ownership":{"direct":true},"balance_after":5800,"source":{"system":"sec-edgar","filing":"0000899243-20-024803","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000089924320024803/doc4.xml","form_type":"4"}},{"id":3092204,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-07-02T16:16:39.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":1499971,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The Reporting Person is a managing partner of Pivotal bioVenture Partners Management Ltd. (\"Investment Advisor\"), which is the investment advisor to Pivotal, and is managing partner of Pivotal bioVenture Partners Investment Advisor, LLC, which is the U.S. sub-advisor to the Investment Advisor. Therefore, the Reporting Person may be deemed to beneficially own the shares held by Pivotal. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1499971},"source":{"system":"sec-edgar","filing":"0001104659-20-080562","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080562/a4.xml","form_type":"4"}},{"id":3092203,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-02T16:16:39.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":5882,"price":17,"value":99994.0,"ownership":{"direct":true},"balance_after":5882,"source":{"system":"sec-edgar","filing":"0001104659-20-080562","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080562/a4.xml","form_type":"4"}},{"id":3092202,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-02T16:16:39.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":294117,"price":17,"value":4999989.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The Reporting Person is a managing partner of Pivotal bioVenture Partners Management Ltd. (\"Investment Advisor\"), which is the investment advisor to Pivotal, and is managing partner of Pivotal bioVenture Partners Investment Advisor, LLC, which is the U.S. sub-advisor to the Investment Advisor. Therefore, the Reporting Person may be deemed to beneficially own the shares held by Pivotal. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":1794088,"source":{"system":"sec-edgar","filing":"0001104659-20-080562","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080562/a4.xml","form_type":"4"}},{"id":3092201,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-02T16:16:39.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":1499971,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The Reporting Person is a managing partner of Pivotal bioVenture Partners Management Ltd. (\"Investment Advisor\"), which is the investment advisor to Pivotal, and is managing partner of Pivotal bioVenture Partners Investment Advisor, LLC, which is the U.S. sub-advisor to the Investment Advisor. Therefore, the Reporting Person may be deemed to beneficially own the shares held by Pivotal. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":1499971,"source":{"system":"sec-edgar","filing":"0001104659-20-080562","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080562/a4.xml","form_type":"4"}},{"id":3092443,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-02T16:05:04.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":8823,"price":17,"value":149991.0,"ownership":{"direct":true},"balance_after":8823,"source":{"system":"sec-edgar","filing":"0000899243-20-018260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320018260/doc4.xml","form_type":"4"}},{"id":3096759,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T06:34:47.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 36 equal monthly installments commencing on July 18, 2020."}],"balance_after":30000,"derivative":{"exercise_price":17,"expiration_date":"2030-06-18","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-017872","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017872/doc4.xml","form_type":"4"}},{"id":3118107,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2020-06-08T20:38:22.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 4, 2021, and (ii) the 2021 annual meeting of the Issuer's stockholders."}],"balance_after":12500,"derivative":{"exercise_price":97.59,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001593968-20-001422","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000159396820001422/primary_01.xml","form_type":"4"}},{"id":3212851,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-12T22:34:35.000Z","date":"2020-03-12","kind":"purchase","acquired":true,"shares":500,"price":74.91,"value":37455.0,"ownership":{"direct":true},"balance_after":5450,"source":{"system":"sec-edgar","filing":"0000899243-20-008109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000089924320008109/doc4.xml","form_type":"4"}},{"id":3212850,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-12T22:34:35.000Z","date":"2020-03-12","kind":"purchase","acquired":true,"shares":500,"price":73,"value":36500.0,"ownership":{"direct":true},"balance_after":4950,"source":{"system":"sec-edgar","filing":"0000899243-20-008109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000089924320008109/doc4.xml","form_type":"4"}},{"id":3212849,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-12T22:34:35.000Z","date":"2020-03-12","kind":"purchase","acquired":true,"shares":500,"price":70,"value":35000.0,"ownership":{"direct":true},"balance_after":4450,"source":{"system":"sec-edgar","filing":"0000899243-20-008109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000089924320008109/doc4.xml","form_type":"4"}},{"id":3212848,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-12T22:34:35.000Z","date":"2020-03-12","kind":"purchase","acquired":true,"shares":550,"price":69.1687,"value":38042.785,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $68.69 to $69.4791, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3950,"source":{"system":"sec-edgar","filing":"0000899243-20-008109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000089924320008109/doc4.xml","form_type":"4"}},{"id":3212847,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-12T22:34:35.000Z","date":"2020-03-10","kind":"purchase","acquired":true,"shares":1000,"price":80,"value":80000.0,"ownership":{"direct":true},"balance_after":3400,"source":{"system":"sec-edgar","filing":"0000899243-20-008109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000089924320008109/doc4.xml","form_type":"4"}},{"id":3313067,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-10T21:48:51.000Z","date":"2020-01-09","kind":"purchase","acquired":true,"shares":788,"price":70.5,"value":55554.0,"ownership":{"direct":true},"balance_after":2400,"source":{"system":"sec-edgar","filing":"0000899243-20-000978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000089924320000978/doc4.xml","form_type":"4"}},{"id":3315918,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-07T23:09:08.000Z","date":"2020-01-03","kind":"purchase","acquired":true,"shares":1138,"price":70,"value":79660.0,"ownership":{"direct":true},"balance_after":1612,"source":{"system":"sec-edgar","filing":"0000899243-20-000737","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000089924320000737/doc4.xml","form_type":"4"}},{"id":3315917,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-07T23:09:08.000Z","date":"2020-01-03","kind":"purchase","acquired":true,"shares":289,"price":69,"value":19941.0,"ownership":{"direct":true},"balance_after":474,"source":{"system":"sec-edgar","filing":"0000899243-20-000737","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000089924320000737/doc4.xml","form_type":"4"}},{"id":3321447,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-03T22:13:10.000Z","date":"2019-12-31","kind":"purchase","acquired":true,"shares":185,"price":70,"value":12950.0,"ownership":{"direct":true},"balance_after":185,"source":{"system":"sec-edgar","filing":"0000899243-20-000296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000089924320000296/doc4.xml","form_type":"4"}},{"id":3388579,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:01:53.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.  The shares subject to this option are fully vested as of the date hereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."}],"balance_after":0,"derivative":{"exercise_price":16.9,"expiration_date":"2027-05-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-053916","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053916/doc4.xml","form_type":"4"}},{"id":3388578,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:01:53.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option shall fully vest and become exercisable on the date of the 2017 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.  The shares subject to this option are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":29.26,"expiration_date":"2026-05-25","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-053916","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053916/doc4.xml","form_type":"4"}},{"id":3388577,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:01:53.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":6350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall fully vest and become exercisable on the date of the 2016 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.  The shares subject to this option are fully vested as of the date hereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":39.66,"expiration_date":"2025-05-18","underlying":"Common Stock","underlying_shares":6350},"source":{"system":"sec-edgar","filing":"0001209191-19-053916","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053916/doc4.xml","form_type":"4"}},{"id":3474301,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-01T23:18:16.000Z","date":"2019-06-27","kind":"grant","acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 27, 2020, and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":16250,"derivative":{"exercise_price":16,"expiration_date":"2029-06-27","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0000899243-19-018725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000089924319018725/doc4.xml","form_type":"4"}},{"id":3480924,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-21T20:03:07.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":6.12,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-19-037002","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000110465919037002/a4.xml","form_type":"4"}},{"id":3491342,"issuer":{"id":116495,"kind":"organization","name":"OTONOMY, INC.","symbol":"OTIC"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-13T17:04:07.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date."}],"balance_after":17500,"derivative":{"exercise_price":2.35,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-19-036837","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493566/000120919119036837/doc4.xml","form_type":"4"}},{"id":3800548,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche B Convertible Preferred Stock","published_at":"2018-10-03T01:40:28.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":9502249,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The Reporting Person is a managing partner of Pivotal bioVenture Partners Management Ltd. (\"Investment Advisor\"), which is the investment advisor to Pivotal, and is managing partner of Pivotal bioVenture Partners Investment Advisor, LLC, which is the U.S. sub-advisor to the Investment Advisor. Therefore, the Reporting Person may be deemed to beneficially own the shares held by Pivotal.  The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":458425},"source":{"system":"sec-edgar","filing":"0001209191-18-053538","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000120919118053538/doc4.xml","form_type":"4"}},{"id":3800547,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche A Convertible Preferred Stock","published_at":"2018-10-03T01:40:28.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":7446904,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The Reporting Person is a managing partner of Pivotal bioVenture Partners Management Ltd. (\"Investment Advisor\"), which is the investment advisor to Pivotal, and is managing partner of Pivotal bioVenture Partners Investment Advisor, LLC, which is the U.S. sub-advisor to the Investment Advisor. Therefore, the Reporting Person may be deemed to beneficially own the shares held by Pivotal.  The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":359267},"source":{"system":"sec-edgar","filing":"0001209191-18-053538","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000120919118053538/doc4.xml","form_type":"4"}},{"id":3800546,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T01:40:28.000Z","date":"2018-09-28","kind":"purchase","acquired":true,"shares":337724,"price":15,"value":5065860.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The Reporting Person is a managing partner of Pivotal bioVenture Partners Management Ltd. (\"Investment Advisor\"), which is the investment advisor to Pivotal, and is managing partner of Pivotal bioVenture Partners Investment Advisor, LLC, which is the U.S. sub-advisor to the Investment Advisor. Therefore, the Reporting Person may be deemed to beneficially own the shares held by Pivotal.  The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":1180178,"source":{"system":"sec-edgar","filing":"0001209191-18-053538","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000120919118053538/doc4.xml","form_type":"4"}},{"id":3800545,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T01:40:28.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":458425,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes an aggregate of 24,762 shares of Common Stock received by Pivotal upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The Reporting Person is a managing partner of Pivotal bioVenture Partners Management Ltd. (\"Investment Advisor\"), which is the investment advisor to Pivotal, and is managing partner of Pivotal bioVenture Partners Investment Advisor, LLC, which is the U.S. sub-advisor to the Investment Advisor. Therefore, the Reporting Person may be deemed to beneficially own the shares held by Pivotal.  The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":842454,"source":{"system":"sec-edgar","filing":"0001209191-18-053538","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000120919118053538/doc4.xml","form_type":"4"}},{"id":3800544,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T01:40:28.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":359267,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The Reporting Person is a managing partner of Pivotal bioVenture Partners Management Ltd. (\"Investment Advisor\"), which is the investment advisor to Pivotal, and is managing partner of Pivotal bioVenture Partners Investment Advisor, LLC, which is the U.S. sub-advisor to the Investment Advisor. Therefore, the Reporting Person may be deemed to beneficially own the shares held by Pivotal.  The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":359267,"source":{"system":"sec-edgar","filing":"0001209191-18-053538","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606826/000120919118053538/doc4.xml","form_type":"4"}},{"id":3887175,"issuer":{"id":116495,"kind":"organization","name":"OTONOMY, INC.","symbol":"OTIC"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-20T19:37:29.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date."}],"balance_after":17500,"derivative":{"exercise_price":4.45,"expiration_date":"2028-06-18","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-18-038876","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493566/000120919118038876/doc4.xml","form_type":"4"}},{"id":4257152,"issuer":{"id":116495,"kind":"organization","name":"OTONOMY, INC.","symbol":"OTIC"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-07-14T18:35:57.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the date of the Issuer's next annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":16.05,"expiration_date":"2027-06-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-045258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493566/000120919117045258/doc4.xml","form_type":"4"}},{"id":4302892,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-26T18:27:55.000Z","date":"2017-05-24","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date."}],"balance_after":15000,"derivative":{"exercise_price":16.9,"expiration_date":"2027-05-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-036020","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117036020/doc4.xml","form_type":"4"}},{"id":4481795,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-01-25T16:15:59.000Z","date":"2017-01-23","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable in equal annual installments on each of the first three anniversaries of the date of the grant (provided that, in any case, the option will fully vest on the day prior to the annual meeting for the third fiscal year following the date of the grant)."}],"balance_after":4500,"derivative":{"exercise_price":18.54,"expiration_date":"2027-01-22","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0000903423-17-000030","document":"prestonf4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000090342317000030/prestonf4.xml","form_type":"4"}}]}